Skip to main content
Midas Edge

Edgewise Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

EWTX$46.53-4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

​​​​​​​​​​​​​
​ · ​ · Three months ended September 30, · ​ · Nine months ended September 30,
​2025202420252024
​​​​​​​​​​​​​
Operating expenses · ​ · ​ · ​ · ​ · ​ · ​
Research and development​$37,480​$32,222​$107,795$90,596
General and administrative​9,378​8,210​27,632​22,696
Total operating expenses​46,858​40,432​135,427​113,292
​​​​​​​​​​​​​
Loss from operations​(46,858)​(40,432)​(135,427)​(113,292)
​​​​​​​​​​​​​
Other income​​​​
Interest income​6,192​6,303​17,848​19,141
Total other income​6,192​6,303​17,848​19,141
​​​​​​​​​​​​​
Net loss​​(40,666)​​(34,129)​​(117,579)​​(94,151)
​​​​​​​​​​​​​
Other comprehensive income (loss):​​​​​​​​​​​​
Unrealized gain on available-for-sale securities​​497​​2,105​​281​​952
Total comprehensive loss​$(40,169)​$(32,024)​$(117,298)​$(93,199)
​​​​​​​​​​​​​
Net loss per share, basic and diluted​$(0.39)​$(0.36)​$(1.15)​$(1.03)
Weighted-average shares outstanding, basic and diluted​105,492,779​93,813,346​101,892,400​91,639,964
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.